Carotid Intervention Selection, Timing, and Peri-Procedural Management

30.1Carotid intervention selection, timing, and peri-procedural management — the working questions

A carotid stenosis becomes an operative problem only after the team has linked the lesion to the patient’s neurological risk, life expectancy, anatomy, and procedural risk. The first distinction is symptomatic versus asymptomatic disease. A recent ipsilateral stroke, transient ischemic attack, or retinal ischemic event changes the urgency of the consultation: the artery is no longer an incidental imaging finding, but a plausible embolic source in a patient whose recurrent-stroke risk is front-loaded. Contemporary ESVS, SVS, and AHA/ASA guidance all treat carotid intervention as part of this broader secondary-prevention pathway rather than as an isolated technical decision Editor's Choice European 2023 · SVS 2022 · AHA 2021.

Next, the stenosis must be severe enough, and sufficiently well characterized, for the trial-derived benefit of revascularization to apply. A generic report of “carotid stenosis” is not an adequate indication. The report must be translated into an ipsilateral, anatomically plausible lesion, with attention to the imaging method, degree of narrowing, plaque distribution, tandem disease, arch and cervical anatomy, intracranial circulation when relevant, and whether the neurological event is likely carotid-territory. If the event mechanism is atrial fibrillation, small-vessel disease, dissection, or another competing source, the benefit of treating a coincidental carotid lesion becomes much less certain, even when the stenosis looks severe.

Modality selection follows. Carotid endarterectomy remains the default reference operation for many symptomatic patients who have surgically accessible disease and acceptable operative risk, particularly in older patients where randomized evidence has favoured CEA over CAS at the peri-procedural horizon CREST · 2010. Stent-based treatment becomes more attractive when the neck is hostile, the lesion is surgically difficult, or the patient’s cardiac and general surgical risk changes the balance. Transfemoral CAS and transcarotid revascularization are distinct: the former exposes the patient to arch manipulation, whereas the latter is positioned for selected patients in whom stenting is reasonable but transfemoral access is anatomically unattractive Editor's Choice European 2023 · SVS 2022.

Finally, the treating operator and center must be able to deliver the required 30-day stroke-or-death performance for the patient’s symptomatic status. The smaller the expected absolute benefit, the less room there is for procedural harm. For symptomatic disease, a higher peri-procedural risk may still be compatible with net benefit than in asymptomatic disease; for asymptomatic disease, the quality threshold is stricter because the stroke-prevention gain is smaller and accrues over time Editor's Choice European 2023 · SVS 2022. In practice, carotid intervention selection is therefore a sequence: confirm that the event and lesion belong together, decide whether revascularization is beneficial, choose the safest durable modality for the patient’s anatomy and comorbidity, and offer it only in a setting whose audited outcomes preserve the expected benefit.

30.2Timing: how soon after a symptomatic event should the artery be addressed?

Timing is the clinical pressure point in symptomatic carotid disease. The benefit of CEA is not evenly distributed across the weeks after stroke or TIA. Pooled symptomatic-trial experience anchored in NASCET and ECST showed that the greatest absolute reduction in subsequent stroke is achieved when endarterectomy is performed within 2 weeks of the qualifying event NASCET · 1991. ESVS 2023 and SVS 2022 carry this principle into contemporary practice by framing the 2-week interval as the practical target for otherwise appropriate symptomatic patients Editor's Choice European 2023 · SVS 2022.

The 2-week target does not imply operating indiscriminately at the first available hour. Hyperacute intervention can be hazardous when the neurological injury is unstable, the infarct burden is large, hemorrhagic transformation is a concern, blood pressure is poorly controlled, or the patient is fluctuating for reasons not yet understood. Defining the neurological trajectory is essential: a non-disabling TIA or minor stroke with a compatible high-grade ipsilateral stenosis is a different patient from one with a large territorial infarct, depressed consciousness, or evolving cerebral edema. In the former, delay loses benefit; in the latter, haste may convert a preventable stroke into a peri-operative catastrophe Editor's Choice European 2023 · SVS 2022.

Operationally, the timing standard belongs to the entire stroke pathway. A patient cannot receive timely CEA if carotid imaging is delayed, if the stenosis report does not specify severity and laterality, if antithrombotic and statin therapy are not started promptly, or if referral is routed through a routine outpatient queue. A functioning pathway identifies possible carotid-territory events at presentation, obtains vascular imaging quickly, distinguishes severe ipsilateral stenosis from incidental disease, and brings the patient to a vascular decision while the 2-week benefit window is still open Editor's Choice European 2023 · AHA 2021.

The timing conversation is different in asymptomatic disease. There is no post-event clock to outrun, and the absolute benefit is smaller. Elective intervention, when justified, should be scheduled after the patient’s cardiovascular risk factors, antiplatelet plan, lipid therapy, blood pressure, renal function, frailty, and competing life-limiting illness have been considered. In symptomatic disease the danger is losing time; in asymptomatic disease the danger is treating a low-risk patient with a procedure whose 30-day hazard may erase the long-term stroke-prevention gain Editor's Choice European 2023 · SVS 2022.

30.3Randomised evidence on CEA versus CAS at 30 days and long term

Randomized evidence demonstrates that CEA and CAS are not interchangeable; outcomes depend on the patient population, symptomatic status, operator selection, era of stent technique, and which peri-procedural event is being counted. CREST is the central modern comparison because it randomized symptomatic and asymptomatic patients to CEA or CAS and found similar overall primary composite outcomes across follow-up, but the early adverse-event profile was different: CAS had more peri-procedural stroke, while CEA had more peri-procedural myocardial infarction CREST 2016 · CREST · 2010. In clinical practice, that distinction matters more than overall equivalence. A patient with high concern about stroke may view the trade-off differently from a patient whose dominant risk is peri-operative cardiac injury.

The symptomatic-only trials make the early neurological risk of CAS difficult to ignore. ICSS reported more early stroke, myocardial infarction, or death after CAS than after CEA in symptomatic patients ICSS · 2010. EVA-3S was stopped early because of excess 30-day stroke or death in the stenting arm Endarterectomy versus Stenting 2006. SPACE failed to establish non-inferiority for stent-protected angioplasty versus CEA at 30 days in symptomatic stenosis SPACE (30-day) 2006. These studies were conducted in an earlier phase of CAS technique and operator experience, but they remain clinically important because symptomatic carotid patients have the least tolerance for additional embolic hazard during the very period when revascularization is meant to reduce recurrent stroke.

SAPPHIRE answers a narrower question. It studied patients considered at high surgical risk and found CAS non-inferior to CEA on a composite endpoint including stroke, myocardial infarction, and death at 30 days Protected Carotid-Artery Stenting 2004. This does not mean all high-risk patients should receive CAS. Instead, high surgical risk changes the outcome weights: avoiding myocardial infarction and avoiding a difficult neck operation may become more important in selected patients, provided the stenting team can keep neurological complications acceptably low. The high-risk label should therefore be unpacked into its components—cardiac risk, pulmonary risk, neck anatomy, lesion accessibility, and expected survival—rather than serving as an automatic indication.

ACST-2 extends the CEA-versus-CAS comparison into asymptomatic patients suitable for either procedure. It reported similar peri-procedural and 5-year non-disabling stroke rates for CEA and CAS in participating centers Second asymptomatic carotid 2021. That finding supports equipoise in selected asymptomatic patients treated by experienced operators, but it does not lower the bar for intervention. Because asymptomatic patients generally have a smaller absolute treatment gain, a center whose 30-day results exceed accepted thresholds may offer harm rather than prevention, even if a trial in selected centers showed comparable modalities.

Pooled data align with these individual trial results. The Cochrane carotid comparison concluded that CAS carries a higher peri-procedural stroke risk than CEA, while long-term non-procedural stroke rates are broadly similar once the patient has passed the peri-procedural period Carotid artery stenting 2020. For clinical decision-making, this separates two questions. First, can the patient safely get through the procedure? Second, once treated successfully, is the artery likely to provide durable stroke prevention? CEA and CAS may look similar on the second question, but the first question often determines the correct modality.

30.4Modality selection: matching CEA, transfemoral CAS, or TCAR to patient profile

Modality selection begins with the patient's specific anatomy and risk profile, rather than institutional habit. In a recently symptomatic patient with surgically accessible bifurcation disease, reasonable life expectancy, and no prohibitive cardiac or neck risk, CEA is usually the reference option. The CREST age interaction is a key factor: outcomes favoured CEA in patients aged 70 years and older, with the difference concentrated in peri-procedural stroke risk CREST · 2010. Age is not an absolute rule, but it is a strong warning against treating an older symptomatic patient with transfemoral CAS simply because it appears less invasive.

The case for CAS strengthens when the risk of open surgery is unusually high or the surgical field is unfavourable. Prior neck radiation, previous neck dissection, restenosis after endarterectomy, a very high lesion, hostile soft tissue, cranial nerve vulnerability, or severe cardiopulmonary disease may all shift the balance away from standard CEA. Even then, technical feasibility is only part of the assessment. The team must ask whether embolic protection can be used effectively, whether the lesion can be crossed safely, whether the access route is acceptable, and whether the operator’s 30-day outcomes preserve the expected benefit Editor's Choice European 2023 · SVS 2022.

Transfemoral CAS is most vulnerable when the route to the lesion is itself diseased. A heavily calcified or shaggy aortic arch, marked arch elongation, tortuous innominate or common-carotid anatomy, and severe proximal common-carotid disease increase the amount of manipulation needed before the stenosis is even treated. Contemporary society guidelines position transcarotid revascularization for these exact situations, serving as an alternative access strategy for selected stent candidates in whom arch traversal is undesirable, rather than a universal replacement for CEA Editor's Choice European 2023 · SVS 2022. The older SVS guidance is useful historically because it predates much of the current TCAR experience and shows how rapidly the access discussion has evolved SVS 2011.

Decision-making therefore balances competing hazards. Older age, recent symptoms, and straightforward cervical exposure generally pull the decision toward CEA. Hostile neck anatomy, severe cardiac vulnerability, or prior local treatment may pull it toward a stent-based option. Hostile arch anatomy pulls away from transfemoral CAS and toward a transcarotid strategy when stenting is otherwise appropriate. None of these features alone should override the whole clinical picture. A frail asymptomatic patient with limited life expectancy may be best served by medical therapy even if the anatomy is technically favorable; a symptomatic patient with a hostile neck and a hostile arch may require multidisciplinary selection among imperfect options rather than reflexive treatment.

Shared decision-making should be explicit about what each procedure is trying to avoid. CEA avoids arch manipulation and has the strongest symptomatic evidence base, but it exposes the patient to cervical incision, cranial nerve injury risk, wound complications, and peri-operative cardiac stress. Transfemoral CAS avoids the neck incision but may increase embolic risk in older patients and in difficult arches. TCAR seeks to reduce arch-related embolic hazard in selected stent candidates, but its use should remain tied to patient selection, local expertise, and contemporary outcome monitoring Editor's Choice European 2023 · SVS 2022.

30.5Peri-procedural 30-day stroke or death targets as the gatekeeper

The 30-day stroke-or-death rate is the gatekeeper for carotid intervention because the procedure is preventive. A technically beautiful repair that causes an early stroke has failed the purpose of treatment. Contemporary ESVS and SVS guidance frame acceptable peri-procedural performance differently for symptomatic and asymptomatic disease, commonly using thresholds of ≤6% 30-day stroke or death for symptomatic patients and ≤3% for asymptomatic patients Editor's Choice European 2023 · SVS 2022. The asymptomatic threshold is stricter because the untreated short-term risk is usually lower and the procedural hazard has more time to cancel the long-term benefit.

These thresholds should be applied to the relevant population and modality, rather than averaged across all cases. A center may have excellent CEA outcomes but limited CAS experience; an operator may perform well in asymptomatic elective cases but have worse results in urgent symptomatic patients; a program may do well overall while a subgroup with hostile arch anatomy performs poorly. The quality question is therefore specific: for this patient’s symptomatic status, anatomy, urgency, and proposed procedure, is the treating team’s 30-day stroke-or-death performance within the range that allows net benefit? If the answer is uncertain, referral to a higher-volume or more experienced carotid center may be the safer intervention.

Quality targets also discipline the asymptomatic consultation. The patient with asymptomatic stenosis usually has time for careful risk-factor optimization and for a sober discussion of competing risks. If the expected absolute stroke-prevention benefit is modest, then even a small excess in 30-day harm can erase it. Consequently, asymptomatic intervention should not be offered solely because a stenosis is severe on imaging. It should be offered only when the patient has a reasonable life expectancy, the lesion and patient profile suggest meaningful future stroke risk, best medical therapy is addressed, and the operator’s results meet the stricter 30-day standard Editor's Choice European 2023 · SVS 2022.

Peri-procedural management is part of the same quality system. The AHA/ASA secondary-prevention guideline places carotid intervention within a pathway that includes antiplatelet treatment, lipid lowering, blood-pressure control, diabetes and smoking management when relevant, and investigation of competing stroke mechanisms AHA 2021. The 2017 ESC peripheral arterial disease guideline reinforces the same principle from a vascular-medicine perspective: extracranial carotid disease is usually one expression of multi-bed atherosclerosis, so treatment should address coronary, lower-limb, renal, and systemic cardiovascular risk rather than the bifurcation alone Aboyans ESC lower-limb PAD 2017.

A sound clinical habit is to explicitly consider the intended quality threshold before recommending the procedure. In symptomatic disease, the question is whether timely intervention can be delivered with an acceptably low early stroke-or-death risk. In asymptomatic disease, the question is whether the patient is likely to live long enough and remain well enough to benefit after the early hazard has been paid. CEA, transfemoral CAS, and TCAR can all be reasonable in selected patients, but none is justified when the expected 30-day harm exceeds the standard that makes preventive carotid treatment worthwhile Editor's Choice European 2023 · SVS 2022.